CEO Annual Letter to Shareholders | Takeda Pharmaceuticals

CEO Annual Letter to Shareholders

Dear Takeda Shareholder,

On behalf of the Takeda Board of Directors, I am delighted to invite you to our Annual Shareholders Meeting on June 26, 2024.

I would like to take this opportunity to highlight some of the major trends in the global macro and health care environments and discuss our strategy for resilience and growth.

As we had anticipated, Fiscal Year 2023 (FY2023) was a challenging year for our business, with revenue and profit impacted by generic competition for several of our large medications. Nevertheless, I’m pleased to report that we delivered or exceeded our Management Guidance for year-on-year Core revenue and profit performance at Constant Exchange Rate.

We now have a clear line of sight back to growth after this period of generic exposure, thanks to our portfolio of Growth & Launch Products and our innovative pipeline of promising candidate therapies. Before describing the outstanding progress with our pipeline, I will give my perspective on how the environment has been evolving.

Continue reading below using the +

Christophe Weber

Dedicated to sustainable value for shareholders

I am grateful for your trust and support as we pursue our mission. I look forward to engaging with you at the Annual Shareholders Meeting and to a future where we will continue to build on our legacy of innovation and our commitment to improving the lives of patients around the world.

Warm regards,

CEO signature

Christophe Weber, President & CEO Takeda Pharmaceutical Company Limited